Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs

• Published in: Frontiers in immunology Vol. 16; p. 1570717
• Main Authors: Maekawa, Naoya, Konnai, Satoru, Watari, Kei, Takeuchi, Hiroto, Nakanishi, Takeshi, Tachibana, Taro, Hosoya, Kenji, Kim, Sangho, Kinoshita, Ryohei, Owaki, Ryo, Yokokawa, Madoka, Kagawa, Yumiko, Takagi, Satoshi, Deguchi, Tatsuya, Ohta, Hiroshi, Kato, Yukinari, Yamamoto, Satoshi, Yamamoto, Keiichi, Suzuki, Yasuhiko, Okagawa, Tomohiro, Murata, Shiro, Ohashi, Kazuhiko
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 20.05.2025
• Subjects: Animals; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; canine tumor; CTLA-4 Antigen - antagonists & inhibitors; CTLA-4 Antigen - immunology; cytotoxic T lymphocyte associated protein 4 (CTLA-4); Dog Diseases - drug therapy; Dog Diseases - immunology; Dogs; Female; immune checkpoint inhibitors; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immunology; Immunotherapy; Male; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - veterinary; programmed death ligand 1 (PD-L1); Salvage Therapy; canine tumor; programmed death ligand 1 (PD-L1); immune checkpoint inhibitors; cytotoxic T lymphocyte associated protein 4 (CTLA-4); immunotherapy

Immune checkpoint inhibitors (ICIs) are widely used for cancer immunotherapy; however, the clinical efficacy of anti-PD-1/PD-L1 monotherapy is generally limited, highlighting the need to develop combination therapies. Dogs develop spontaneous tumors in immunocompetent settings, and anti-PD-1/PD-L1 a...